Galapagos creates new warrant plan
(Thomson Reuters ONE) -
Mechelen, Belgium; 1 May 2015 - Galapagos NV (Euronext: GLPG) announced today
that its Board of Directors created 625,740 warrants under a new warrant plan
for the benefit of employees, directors and an independent consultant of the
Company and its subsidiaries.
On 30 April 2015, the Board of Directors of Galapagos approved the "Warrant Plan
2015" within the framework of the authorized capital. Under this warrant plan,
625,740 warrants were created, subject to acceptances.
The warrants created under Warrant Plan 2015 were offered on 30 April 2015,
mainly to employees of Galapagos and its subsidiaries and in secondary order to
its directors and an independent consultant. The offer of warrants to directors
has been pre-approved by the Annual Shareholders' Meeting held on 28 April 2015.
The warrants have an exercise term of eight years as of the date of the offer
and have an exercise price of ?28.75 (the average closing price of the share on
Euronext Brussels during the thirty days preceding the date of the offer). The
warrants are not transferable and can in principle not be exercised prior to the
end of the third calendar year after the calendar year in which they were
granted to the beneficiaries. Each warrant gives the right to subscribe to one
new Galapagos share. Should the warrants be exercised, Galapagos will apply for
the listing of the resulting new shares on a regulated stock market. The
warrants as such will not be listed on any stock market.
To date, Galapagos' total share capital amounts to ?166,996,209.57; the total
number of securities conferring voting rights is 30,870,677, which is also the
total number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 3,019,305, which equals the total number of voting rights that may
result from the exercise of these warrants, and excludes the 625,740 warrants of
Warrant Plan 2015 which were created subject to acceptances. Galapagos does not
have any convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other indications. In
the field of inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. Galapagos reported good
activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2
trials in RA. AbbVie and Galapagos also signed a collaboration agreement in
cystic fibrosis to develop and commercialize molecules that address mutations in
the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and
corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-
in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being
tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown
favorable safety in a Phase 1 trial and is expected to enter Phase 2 in
idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements concerning anticipated progress, objectives and
expectations regarding the commercial potential of our product candidates,
intended product development, clinical activity timing, and other objectives and
explanations, all of which involve certain risks and uncertainties. These
statements are often, but are not always, made through the use of words or
phrases such as "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially different from
any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Among the
factors that may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product development
activities, regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1918051]
Unternehmensinformation / Kurzprofil:
Datum: 01.05.2015 - 18:00 Uhr
Sprache: Deutsch
News-ID 390247
Anzahl Zeichen: 7272
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 137 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos creates new warrant plan"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
